Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021

Rhea-AI Summary

Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on May 4, 2021, at 8:30 a.m. ET to discuss its Q1 2021 results and provide a business update. The call can be accessed at 844-277-9450 (domestic) and 336-525-7139 (international) using conference ID 9967338. The company is known for its microbiome therapeutics, particularly the SER-109 program, which has received FDA's Breakthrough Therapy and Orphan Drug designations for treating recurrent C. difficile infection. Its SER-287 and SER-301 programs are also advancing through clinical trials.

Positive

• SER-109 achieved positive pivotal clinical results.
• Obtained Breakthrough Therapy and Orphan Drug designations from the FDA.
• SER-287 is in a Phase 2b study for ulcerative colitis with Fast Track and Orphan Drug designations.

Negative

• None.

Seres Therapeutics, Inc. (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2021 at 8:30 a.m. ET to discuss first quarter 2021 results and provide a general business update.

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 9967338. To join the live webcast, please visit the “Investors and Media” section of the Seres website at www.serestherapeutics.com.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005110/en/

FAQ

What are the key highlights of Seres Therapeutics Q1 2021 results?

Seres Therapeutics will discuss Q1 2021 results during its conference call on May 4, 2021.

What is the status of SER-109 program by Seres Therapeutics?

The SER-109 program achieved positive pivotal clinical results and has received FDA's Breakthrough Therapy and Orphan Drug designations.

What are the clinical trials currently conducted by Seres Therapeutics?

Seres is conducting studies for SER-109 for C. difficile infection, SER-287 for ulcerative colitis, and SER-301 to prevent gastrointestinal infections.